OROCSON study: Late Onset Recurrent Ovarian Cancer: Surgery Or Not

Completed

• Conditions: Ovarian cancer; Cancer; Malignant neoplasm of ovary

• Registration Number: ISRCTN50678517
• Lead Sponsor: Erasmus Medical Centre (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-12-20
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 700

Inclusion Criteria

1. Recurrence of epithelial ovarian cancer
2. After first line chemotherapy with a disease-free interval of at least 6 months
3. Aged greater than 18 years
4. World Health Organization (WHO) Performance Status 0 - 2
5. First-line therapy should have consisted of at least four courses of either cisplatin or carboplatin

Exclusion Criteria

1. More than one line chemotherapy
2. Complete bowel obstruction
3. Metastasised carcinoma (other tumour)
4. Leptomeningeal or brain metastases

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival.

Secondary Outcome Measures

Name	Time	Method
1. Survival<br>2. Toxicity<br>3. Surgical treatment related complications <br>4. Quality of life